Janssen Halts Clinical Development of Alzheimer’s Candidate Atabecestat Due to Liver Issues

Janssen Halts Clinical Development of Alzheimer’s Candidate Atabecestat Due to Liver Issues
Janssen pulled the plug on a Phase 2b/3 trial and a Phase 2 safety study of its Alzheimer’s disease experimental therapy atabecestat due to toxicity issues as a result of serious elevations in liver enzymes seen in some study participants. Atabecestat is a BACE inhibitor, intended to slow cognitive impairment. This enzyme mediates the production of

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *